CMS corrects Stage 2 proposed rule

Jeff Byers | | Health Exec | Economics
Editing Process - 127.52 Kb
The Centers for Medicare & Medicaid Services (CMS) has corrected the Stage 2 meaningful use Notice of Proposed Rulemaking.

The document corrects technical errors and typographical errors in the proposed rule which appeared March 7 in the Federal Register.

As typos go, most are pretty uninteresting. However, CMS provided some crucial details omitted in the previous draft, including:
  • "On page 13707, in our discussion regarding eligible professionals who practice in multiple locations, we inadvertently omitted the timeframe by which the determination is made on whether a practice/location is equipped with Certified EHR Technology.
  • "On page 13711, in our solicitation of comments regarding the variations among facility types for an e-prescribing measure, we inadvertently stated an erroneous threshold percentage.
  • "On pages 13760 through 13763, in Table 9, we incorrectly listed some of the measure stewards and their respective contact information."

The corrected draft was published in the Federal Register on April 18. 

Jeff Byers

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.